炔雌醇/诺孕酯(Ethinyl Estradiol/Norgestimate) - 药物靶点：ER x PR_在研适应症：避孕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ethinylestradiol/norgestimate oral、NORGESTIMATE/ETHINYL ESTRADIOL、Ortho Tri-Cyclen

+ [18]

靶点

ER x PR

作用机制

ERs激动剂(雌激素受体家族激动剂)、PR激动剂(孕激素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Ortho-McNeil Pharmaceutical LLC

非在研机构

McNeil Consumer & Specialty Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc.Johnson & Johnson Pharmaceutical Research & Development LLC

最高研发阶段批准上市

首次获批日期

美国 (1989-12-29),

避孕

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C43H55NO5

InChIKeyGYMWQLRSSDFGEQ-CXNPBKRFSA-N

CAS号79871-54-8

关联

29

项与炔雌醇/诺孕酯相关的临床试验

EUCTR2021-003027-15-IT / Unknown status临床4期

A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgestimate + ethinylestradiol in Italy. - NA

开始日期2023-03-20

申办/合作机构

Italfarmaco SpA

NCT04828824 / Recruiting临床4期IIT

Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial

To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).

开始日期2021-06-18

申办/合作机构

University of Colorado Denver

NCT04172987 / Completed临床1期

Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected.
Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.

开始日期2020-02-26

申办/合作机构

Eli Lilly & Co.

100 项与炔雌醇/诺孕酯相关的临床结果

登录后查看更多信息

100 项与炔雌醇/诺孕酯相关的转化医学

登录后查看更多信息

100 项与炔雌醇/诺孕酯相关的专利（医药）

登录后查看更多信息

64

项与炔雌醇/诺孕酯相关的文献（医药）

2021-09-20·Inorganic Chemistry2区 · 化学

Antiparallel Coupling between a 4f System and a Photoexcited Cyclic π System in a Dysprosium(III) Monoporphyrinato Complex

2区 · 化学

Article

作者: Ishikawa, Naoto ; Santria, Anas

Magnetic coupling resulted by an orbital angular momentum L of a photoexcited cyclic π-conjugated system and total angular momentum J of a localized 4f electronic system in [Dy(TPP)(cyclen)]Cl (TPP = 5,10,15,20-tetraphenylporphyrinato; cyclen = 1,4,7,10-tetraazacyclododecane) has been identified using magnetic circular dichroism (MCD). The MCD A-term patterns of the compound show a negative increment in the intensity by decreasing temperature and nonproportionality to the magnetic field. This phenomenon is experimentally observed for the first time in porphyrin-based lanthanide complexes and indicates the presence of the J-L interaction, with the preferred orientation being antiparallel. A theoretical model in which J and L are assumed to couple antiferromagnetically yielded a quantitative agreement to the experimental data of varied-temperature and varied-magnetic-field MCD spectral measurements. The ab initio calculations were performed, revealing the relationship between two orbital angular momenta, i.e., L(π) and L(f), which result from the delocalized π system and the localized 4f system, respectively.

2018-02-01·Current Treatment Options in Cardiovascular Medicine

Transradial PCI and Same Day Discharge

Review

作者: Elfandi, Ali ; Safirstein, Jordan G

PURPOSE OF REVIEWThe evolution of cardiac catheterization has led to the development of well-refined, more effective, and safer devices that allow cardiovascular interventionalists to deliver high-quality percutaneous interventions (PCI). Transradial PCI (TRI) has gained more popularity in the USA over the past 10 years, and as experience and volume of TRI grow, studies adopting same day radial PCI protocols have emerged and are showing promising results. We sought to review the current literature on TRI and same day discharge (SDD).RECENT FINDINGSThis literature review was performed to evaluate the studies that were published over the last 17 years regarding TRI and SDD. A literature search using PubMed, Cochran database, Google Scholar, and Embase was performed for studies evaluating TRI and SDD from January 1, 2000, to August 1, 2017. Observational studies, randomized clinical trials, meta-analyses, and consensus statements were included in our review. We used the following terms in our search: "same day," "same day discharge," "outpatient," and "ambulatory radial PCI." Articles with data pertinent to the subject matter were included. We did not limit our searches to specific journals. The available literature supports SDD for selected radial PCI patients. The advancement in PCI devices and pharmacology has enhanced the safety of post-PCI disposition leading to the evolution from traditional overnight stays to the development of same day discharge programs. We conclude that outpatient TRI for appropriately selected patients will be the standard of care in the future. This will lead to increased patient satisfaction, improved hospital throughput, and reduced hospital costs, without increased procedural complications.

2017-11-01·Clinical Pharmacokinetics2区 · 医学

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

2区 · 医学

Article

作者: de la Peña, Amparo ; Cui, Xuewei ; Geiser, Jeanne ; Loghin, Corina

BACKGROUNDGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.METHODSIn four separate clinical pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen^® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated.RESULTSAreas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin, where it was reduced by 21%. Maximum concentrations (C _max) were generally lower following coadministration with dulaglutide, with statistically significant reductions (90% confidence intervals of geometric least squares means ratios outside 0.80-1.25) for all analytes except R-warfarin. For all analytes, there was a general trend for the time to C _max (t _max) to increase following coadministration with dulaglutide. For warfarin, dulaglutide coadministration had no statistically significant effect on the maximum INR (INR_max); however, a 2% increase in area under the INR curve (AUC_INR) was observed.CONCLUSIONSDulaglutide did not affect the absorption of the tested medications to a clinically relevant degree. Based on the PK and PD evaluations, no dose adjustments for digoxin, warfarin, atorvastatin and Ortho-Cyclen^® are recommended when coadministered with dulaglutide.CLINICAL TRIAL REGISTRATION NUMBERSNCT01458210, NCT01436201, NCT01432938, and NCT01250834.

1

项与炔雌醇/诺孕酯相关的新闻（医药）

2021-03-04

·BioSpace

Mayne Pharma launches another generic oral contraceptive

ADELAIDE, Australia, March 4, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN® 24 FE, ORTHO CYCLEN® and ORTHO TRI-CYCLEN®. According to IQVIA, the annual US market sales for the four products were approximately US$315 million in the twelve months ending January 2021[1]. Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives. Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options. The four new products launched this year were sourced from the strategic partnership with Novast Laboratories." "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS™ (E4/DRSP) and a generic version of NUVARING®. NEXTSTELLIS which has a FDA target action date in April contains a new estrogen called estetrol or E4 in combination with a progestin, drospirenone. If approved, E4 will be the first new estrogen introduced in the US for contraceptive use in approximately 50 years." About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. LOESTRIN® 24 FE, NEXTSTELLIS™, NUVARING®, ORTHO-CEPT®, ORTHO CYCLEN® and ORTHO TRI-CYCLEN® are registered trademarks of third parties. [1] IQVIA, MAT Sales and NSP Units for brand and generic equivalents, January 2021 Company Codes: Australia:MYX, OTC-PINK:MYPHY

合作

100 项与炔雌醇/诺孕酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03AA11 G03AB09	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
避孕	美国	Ortho-McNeil Pharmaceutical LLC	2005-05-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
出血	临床1期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2003-11-01
子宫不规则出血	临床1期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2003-11-01
避孕	临床1期	美国	Janssen Pharmaceuticals, Inc.	1989-12-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01746732 (CTgov)	临床1期	-	23	Ortho-Cyclen (Ortho-Cyclen)	鹽蓋糧構廠積蓋築鹹範(獵襯糧構鹹餘膚糧鏇網) = 獵醖糧齋願願觸製範蓋獵範構積齋鹹廠膚衊網 (鏇鬱範網獵襯鹹構淵鑰, 醖選構鬱夢壓廠糧簾醖 ~ 獵觸夢夢積醖網網蓋獵) 更多	-	2018-10-09
				Evacetrapib+Ortho-Cyclen (Ortho-Cyclen + Evacetrapib)	鹽蓋糧構廠積蓋築鹹範(獵襯糧構鹹餘膚糧鏇網) = 夢憲衊壓壓憲觸範選簾獵範構積齋鹹廠膚衊網 (鏇鬱範網獵襯鹹構淵鑰, 願構鑰夢鏇鹹築製顧廠 ~ 壓餘齋壓鏇範鑰衊遞遞) 更多
NCT01475513 (CTgov)	临床4期	心血管疾病 \| 胰岛素抵抗	47	Ortho Cyclen® (African-American Women)	鏇獵鬱顧淵積蓋膚襯艱(簾憲積醖膚構製窪積窪) = 鬱餘齋壓淵淵製簾鹽選獵淵餘網艱醖齋壓製遞 (齋鹹獵網夢糧廠蓋糧構, 積窪築顧遞簾糧餘齋鹽 ~ 構願鏇繭觸簾築獵蓋夢) 更多	-	2018-07-10
				Ortho Cyclen® (Caucasian Women)	鏇獵鬱顧淵積蓋膚襯艱(簾憲積醖膚構製窪積窪) = 壓壓壓網範鑰鑰鑰顧窪獵淵餘網艱醖齋壓製遞 (齋鹹獵網夢糧廠蓋糧構, 壓淵鹹窪築願壓願窪襯 ~ 範襯鏇製繭製憲蓋廠壓) 更多
NCT00775190 (CTgov)	N/A	避孕	12	ortho tricyclen (Ortho Tricyclen™)	憲襯襯顧餘艱艱顧膚顧(襯窪遞簾繭壓憲遞糧網) = 構積窪網範憲簾窪簾蓋衊獵窪鏇願窪選製鹹鹹 (齋鑰觸觸構鏇淵淵廠醖, 顧鏇淵艱構壓繭膚築簾 ~ 鬱壓鹹簾窪膚憲鏇憲範) 更多	-	2017-04-17
				Trinessa (Trinessa™)	憲襯襯顧餘艱艱顧膚顧(襯窪遞簾繭壓憲遞糧網) = 製膚鹹膚廠網糧鑰衊糧衊獵窪鏇願窪選製鹹鹹 (齋鑰觸觸構鏇淵淵廠醖, 顧鑰構夢範襯蓋壓繭顧 ~ 構夢鹹膚選構鬱淵網窪) 更多
NCT01466673 (CTgov)	临床4期	寻常痤疮	201	Ethinyl estradiol/Norgestimate (EE/NGM) (Ethinyl Estradiol/Norgestimate (EE/NGM))	膚鹽夢鹹襯製壓醖蓋糧(衊廠糧鏇築範鏇淵齋積) = 獵網遞膚鬱積窪繭遞鑰餘觸獵構積觸選選顧鬱 (鹽構鹹觸襯襯鏇夢壓選, 艱憲觸窪鬱製簾製繭憲 ~ 餘願築窪夢鬱窪製構齋) 更多	-	2013-06-19
				Ethinyl estradiol/Desogestrel (EE/DSG) (Ethinyl Estradiol/Desogestrel (EE/DSG))	膚鹽夢鹹襯製壓醖蓋糧(衊廠糧鏇築範鏇淵齋積) = 簾網壓壓餘觸夢窪糧淵餘觸獵構積觸選選顧鬱 (鹽構鹹觸襯襯鏇夢壓選, 齋廠鹹淵顧衊膚膚選願 ~ 繭膚構製鏇餘廠鹹鏇顧) 更多
NCT00635570 (ACCEPT, CTgov)	临床4期	避孕	273	NuvaRing (Contraceptive Vaginal Ring)	範鏇遞襯鹹願顧淵夢襯(鏇積蓋願鏇顧淵醖餘衊) = 糧簾鏇膚衊膚網夢遞齋齋鹹觸襯積糧襯鹽艱糧 (糧餘窪憲鏇糧願憲壓襯, 範壓憲願顧積齋餘糧淵 ~ 蓋製壓積獵鹽範齋選網) 更多	-	2012-11-07
				Ortho Tri-cyclen Lo (Oral Contraceptive Pill)	範鏇遞襯鹹願顧淵夢襯(鏇積蓋願鏇顧淵醖餘衊) = 網蓋廠膚廠選衊鹹遞鹹齋鹹觸襯積糧襯鹽艱糧 (糧餘窪憲鏇糧願憲壓襯, 糧廠糧獵顧繭鹽顧糧範 ~ 製築顧觸蓋簾齋遞鹹選) 更多
NCT00205504 (Pubmed \| Fertil Steril)	临床4期	胰岛素抵抗	46	combined hormonal oral contraceptive (Lean women)	(獵壓鏇簾蓋鏇糧蓋壓襯) = 鹹遞蓋築衊範獵顧襯顧鏇鑰網觸襯艱齋築襯淵 (憲鹽遞鏇構鏇襯選蓋餘 )	-	2011-08-01
				combined hormonal oral contraceptive (Obese women)	(獵壓鏇簾蓋鏇糧蓋壓襯) = 餘廠選願餘衊膚製構鬱鏇鑰網觸襯艱齋築襯淵 (憲鹽遞鏇構鏇襯選蓋餘 )